Enliven Therapeutics, Inc. (ELVN) Balance Sheet
As of 2026-06-30 (10-Q), Enliven Therapeutics, Inc. (ELVN) reported total assets of $910.2M, total liabilities of $15.1M and shareholders' equity of $895.1M, according to EquiReason's reading of its SEC filings. Cash and equivalents: $135.5M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
ELVNEnliven Therapeutics, Inc.Follow ELVN — free
—
Price chart with a free account
- Market cap
- 3.0B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 18 Nov, in 25 days
| Line | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | Latest Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 47.7 | 48.3 | 75.5 | 100.1 | 124.1 | 98.9 | 135.5 | |
| Short-term investments | 40.5 | 42.0 | 0.0 | 153.0 | 189.3 | 363.7 | 759.7 | |
| Current assets | 90.4 | 92.7 | 77.8 | 266.2 | 318.1 | 474.9 | 907.3 | |
| Total assets | 90.8 | 93.6 | 83.3 | 271.9 | 325.8 | 476.2 | 910.2 | |
| Current liabilities | 6.2 | 7.2 | 9.7 | 25.9 | 15.9 | 16.6 | 14.2 | |
| Total liabilities | 6.4 | 7.6 | 10.4 | 26.0 | 15.9 | 16.6 | 15.1 | |
| Shareholders' equity | 84.4 | -42.9 | -76.8 | 245.9 | 309.8 | 459.6 | 895.1 |
USD millions · SEC XBRL
Enliven Therapeutics, Inc. — questions
- How much cash does Enliven Therapeutics, Inc. have?
- $135.5M in cash and cash equivalents as of 2026-06-30.
- What are Enliven Therapeutics, Inc.'s total assets?
- $910.2M as of 2026-06-30.
- What is Enliven Therapeutics, Inc.'s shareholders' equity?
- $895.1M as of 2026-06-30.
Every figure on this page comes from Enliven Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.